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The discovery of low-frequency coding variants affecting the risk of coronary
artery disease has facilitated the identification of therapeutic targets.
METHODS

Through DNA genotyping, we tested 54,003 coding-sequence variants covering
13,715 human genes in up to 72,868 patients with coronary artery disease and
120,770 controls who did not have coronary artery disease. Through DNA sequencing, we studied the effects of loss-of-function mutations in selected genes.
RESULTS

We confirmed previously observed significant associations between coronary
artery disease and low-frequency missense variants in the genes LPA and PCSK9.
We also found significant associations between coronary artery disease and lowfrequency missense variants in the genes SVEP1 (p.D2702G; minor-allele frequency,
3.60%; odds ratio for disease, 1.14; P = 4.2×10−10) and ANGPTL4 (p.E40K; minorallele frequency, 2.01%; odds ratio, 0.86; P = 4.0×10−8), which encodes angiopoietinlike 4. Through sequencing of ANGPTL4, we identified 9 carriers of loss-of-function
mutations among 6924 patients with myocardial infarction, as compared with 19
carriers among 6834 controls (odds ratio, 0.47; P = 0.04); carriers of ANGPTL4 lossof-function alleles had triglyceride levels that were 35% lower than the levels
among persons who did not carry a loss-of-function allele (P = 0.003). ANGPTL4
inhibits lipoprotein lipase; we therefore searched for mutations in LPL and identified a loss-of-function variant that was associated with an increased risk of
coronary artery disease (p.D36N; minor-allele frequency, 1.9%; odds ratio, 1.13;
P = 2.0×10−4) and a gain-of-function variant that was associated with protection
from coronary artery disease (p.S447*; minor-allele frequency, 9.9%; odds ratio,
0.94; P = 2.5×10−7).
CONCLUSIONS

We found that carriers of loss-of-function mutations in ANGPTL4 had triglyceride
levels that were lower than those among noncarriers; these mutations were also
associated with protection from coronary artery disease. (Funded by the National
Institutes of Health and others.)
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A

lthough genomewide association
studies have identified more than 56 loci
associated with the risk of coronary artery disease,1-3 the disease-associated variants are
typically common (minor-allele frequency >5%)
and located in noncoding sequences; this has
made it difficult to pinpoint causal genes and
affected pathways. This lack of a causal mechanism has in part hindered the immediate translation of the findings of genomewide association
studies into new therapeutic targets. However,
the discovery of rare or low-frequency codingsequence variants that affect the risk of coronary
artery disease has facilitated advances in the
prevention and treatment of disease. The most
recent example of such advances is the development of a new class of therapeutic agents that is
based on the discovery of the gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9)
as a regulator of low-density lipoprotein (LDL)
cholesterol4 and the discovery that low-frequency
and loss-of-function variants in this gene protect
against coronary artery disease.5,6
Recently, low-frequency coding variation across
the genome was systematically tabulated with the
use of next-generation exome and whole-genome
sequencing data from more than 12,000 persons
of various ancestries (including a major contribution from the National Heart, Lung, and Blood
Institute Exome Sequencing Project). Proteinaltering variants (i.e., nonsynonymous, splice-site,
and nonsense single-nucleotide substitutions)
that were observed at least twice among these
12,000 persons were included in a genotyping
array (hereafter referred to as the exome array).
In addition, the exome array contains previously
described variants from genomewide association
studies, a sparse genomewide grid of common
markers, markers that are informative with regard to ancestry (i.e., African American, Native
American, and European), and some additional
content. Additional information on the design of
the exome array is provided at http://genome.sph
.umich.edu/wiki/Exome_Chip_Design. In this
study, we focused on the 220,231 autosomal
variants that were present on the array and were
expected to alter protein sequence (i.e., missense, nonsense, splice-site, and frameshift
variants) and used these to test the contribution
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of low-frequency coding variation to the risk of
coronary artery disease.

Me thods
Study Design and Participants

We performed a discovery study involving 42,335
patients with coronary artery disease and 78,240
controls from 20 individual studies (hereafter
referred to as the discovery cohort). For variants
with suggestive associations, we sought replication of our findings in an independent study of
30,533 patients and 42,530 controls assembled
from 8 individual studies (hereafter referred to
as the replication cohort). The names of the individual studies and information on the numbers
of participants and phenotypic definitions of patients and controls in the discovery cohort and
the replication cohort are provided in Tables S1
and S2, respectively, in the Supplementary Appendix, available with the full text of this article at
NEJM.org. The 5755 participants from the Bangladesh Risk of Acute Vascular Events (BRAVE)
study and the 22,072 participants from the Pakistan Risk of Myocardial Infarction Study (PROMIS)
were of South Asian ancestry; all other participants were of European ancestry.
Genotyping and Quality Control

Samples were genotyped on the Illumina Human
Exome BeadChip array, version 1.0 or 1.1, or the
Illumina OmniExome array (which includes
markers from the HumanExome BeadChip) in
accordance with the manufacturer’s recommended protocol. Our genotyping methods, as well as
the quality-control procedures that were used
to remove low-quality samples and variants, are
described in the Supplementary Appendix.
Follow-up ANGPTL4 Sequencing

The exon sequences of ANGPTL4 were obtained
from the exome sequences7 of 6924 persons who
had early-onset myocardial infarction and those
of 6834 persons who were free from coronary
artery disease (see the Methods section in the
Supplementary Appendix for details). The names
of the individual studies and information on the
numbers of participants and phenotypic definitions of patients and controls for ANGPTL4 se-
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quencing are provided in Table S3 in the Supple- Diabetes [GoT2D] Consortium, and the Diabementary Appendix.
tes Genetics Replication and Meta-Analysis
[DIAGRAM] Consortium; accessed in NovemStatistical Analysis
ber 2015 at www.t ype2diabetesgenetics.org/).
Of the 220,231 variants on the exome array, Additional details of the risk-factor association
54,003 (covering 13,715 genes) were present in analyses are provided in the Methods section in
our study at sufficient frequency (minor-allele the Supplementary Appendix.
frequency >0.01%) to allow for individual-variant
From the sequencing data, we used linear reassociation testing as described in the Supple- gression to test the association between ANGPTL4
mentary Appendix. In the discovery phase, we loss-of-function alleles and plasma lipid levels
defined a suggestive novel association between in 8085 persons for whom lipid measurements
a variant and the risk of coronary artery disease were available, using models described in the
as one with a meta-analysis P value of 1×10−4 or Supplementary Appendix. We calculated the siglower. For variants with suggestive association, nificance of the association between ANGPTL4
we performed association analysis in the replica- loss-of-function alleles and the risk of coronary
tion studies as described in the Supplementary artery disease with the use of 100,000 studyAppendix. We defined significant novel associa- stratified permutations of case–control phenotions as those that were nominally significant types.
(P<0.05) in the replication cohort and that had
an overall P value of less than 7.7×10−8 in the
R e sult s
discovery and replication cohorts combined (a
Bonferroni-corrected threshold that accounted Low-Frequency Coding Variants Associated
for 54,003 markers with minor-allele frequencies with Coronary Artery Disease
>0.01% being tested initially and 12 markers The discovery cohort comprised 120,575 persons
being tested in the replication cohort).
(42,335 patients and 78,240 controls) (Table S1 in
To test for association between variants and the Supplementary Appendix). In the discovery
risk factors for coronary artery disease, we ex- cohort, we found significant associations beamined the relationship between low-frequency tween low-frequency coding variants in the LPA
variants that were significantly associated with and PCSK9 genes and coronary artery disease
disease in the combined (i.e., discovery and (Table 1). Both gene loci also harbor common
replication) analysis and plasma lipid levels in noncoding variants associated with coronary
10,088 samples from the discovery cohort; in artery disease that had previously been discovorder to minimize any effect of ascertainment ered through genomewide association studies.
bias, we limited the analysis to persons without These variants were also present on the exome
coronary artery disease who had lipid measure- array and had significant associations with coroments available. We also examined the relation- nary artery disease in our study (Table 1). In a
ships between the significantly associated low- conditional analysis, the associations between
frequency variants and blood pressure in 146,562 coronary artery disease and the low-frequency
persons from the Cohorts for Heart and Ag- coding variants in both LPA and PCSK9 were
ing Research in Genomic Epidemiology Plus found to be independent of the associations be(CHARGE+) consortium. Tables S4 and S5 in the tween coronary artery disease and the more
Supplementary Appendix list the individual stud- common variants (Table 1).
ies and numbers of participants that contributed
In addition to the variants in LPA and PCSK9,
to the analyses of plasma lipid levels and blood 12 additional suggestive associations (P<1×10−4)
pressure, respectively. Finally, we queried pub- between low-frequency coding variants and
licly available exome-array data to explore the coronary artery disease were identified in the
relationship between significantly associated low- discovery study (Table S6 in the Supplementary
frequency variants and type 2 diabetes (data from Appendix). We tested for associations between
the Type 2 Diabetes Genetic Exploration by Next- these variants and coronary artery disease among
Generation Sequencing in Multi-Ethnic Samples the 73,063 persons (30,533 patients and 42,530
[T2D-GENES] Consortium, Genetics of Type 2 controls) in the replication cohort (see Tables S2
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Table 1. Low-Frequency Coding Variations Previously Associated with Coronary Artery Disease.*
Locus and SNP

Chromosome and
Nucleotide Position†

Allele 1/
Allele 2

Frequency
of Allele 1

Functional
Effect

Odds
Ratio‡

P Value

Conditional
P Value§

%
LPA
rs3798220

6: 160961137

C/T

1.99

p.I4399M

1.54

9.7×10−24

1.9×10−18

rs2048327

6: 160863532

C/T

37.36

NA

1.09

8.1×10−21

1.8×10−15

1: 55505647

T/G

1.52

p.R46L

0.78

8.0×10−10

1.9×10−7

0.93

1.7×10−8

4.6×10−6

PCSK9
rs11591147
rs11206510

1: 55496039

C/T

18.23

NA

*	NA denotes not applicable, and SNP single-nucleotide polymorphism.
†	Chromosome numbers and positions refer to genome build GRCh37.
‡	Odds ratios are for the development of disease in carriers of allele 1.
§	The conditional P value is the P value from an association test conditioning on the other marker listed in the locus.

Table 2. Novel Low-Frequency Coding Variations Showing Significant Association with Coronary Artery Disease.
Locus and SNP

Chromosome and
Nucleotide Position*

Allele 1/
Allele 2

Frequency
of Allele 1

Functional
Effect

Stage

Odds
Ratio†

P Value

p.D2702G

Discovery

1.14

1.1×10−7

Replication

1.13

1.0×10−3

Combined‡

1.14

4.2×10−10

Discovery

0.87

3.0×10−5

Replication

0.86

3.4×10−4

Combined‡

0.86

4.0×10−8

%
SVEP1 rs111245230

ANGPTL4 rs116843064

9: 113169775

19: 8429323

C/T

3.60

A/G

2.01

p.E40K

*	Chromosome numbers and positions refer to genome build GRCh37.
†	Odds ratios are for the development of disease in carriers of allele 1. P values for testing differences between the effects observed in the discovery and replication results were 0.73 for rs111245230 and 0.11 for rs116843064 (Cochran’s Q test for heterogeneity).
‡	The combined stage refers to a meta-analysis that included 72,868 patients with coronary artery disease and 120,770 controls free from the
disease.

and S6 in the Supplementary Appendix for details). Variants in two genes showed association
in the replication set and reached the genomewide level of significance (P<7.7×10−8) in the
combined data set (Table 2). A missense variant
(encoding p.D2702G; minor-allele frequency,
3.60%) in the gene SVEP1 (which encodes sushi,
von Willebrand factor type A, EGF and pentraxin
domain containing 1) was associated with an increased risk of coronary artery disease, and a lowfrequency missense variant (encoding p.E40K;
minor-allele frequency, 2.01%) in ANGPTL4, which
encodes angiopoietin-like 4, was associated
with protection against coronary artery disease
(Table 2).

n engl j med 374;12

Association between Variants and Risk
Factors for Coronary Artery Disease

We next examined the associations of the SVEP1
p.D2702G and ANGPTL4 p.E40K variants with
plasma lipid levels, blood pressure, and type 2
diabetes to determine whether their associations
with coronary artery disease could potentially be
mediated through an effect on these known risk
factors. To minimize any potential effect of
case–control ascertainment in testing the association with plasma lipid levels, we restricted
our analysis to 10,088 controls who were free
from coronary artery disease and to populationbased samples with available lipid data from the
discovery cohort. The tests of association with
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Effect (95% CI)†

P Value

SVEP1 rs111245230 C allele
LDL cholesterol

0.011 (−0.066 to 0.088)

0.78

HDL cholesterol

0.023 (−0.054 to 0.099)

0.56

Triglycerides

0.050 (−0.025 to 0.125)

Systolic blood pressure

0.94 (0.58 to 1.3)

3.0×10−7

Diastolic blood pressure

0.57 (0.35 to 0.79)

4.4×10−7

Type 2 diabetes

1.13 (1.10 to 1.16)

0.0062

0.19

ANGPTL4 rs116843064 A allele
LDL cholesterol

−0.064 (−0.153 to 0.025)

HDL cholesterol

0.295 (0.206 to 0.384)

8.2×10−11

Triglycerides

−0.335 (−0.424 to −0.246)

1.6×10−13

Systolic blood pressure

−0.18 (−0.66 to 0.30)

0.46

Diastolic blood pressure

−0.13 (−0.43 to 0.16)

0.38

0.90 (0.87 to 0.92)

0.028

Type 2 diabetes

0.16

ANGPTL4 Loss-of-Function Mutations, Plasma
Lipid Levels, and Coronary Artery Disease

*	Shown in the table are low-frequency variants associated with coronary artery
disease that are outside of known loci that were previously identified in genomewide association studies. CI denotes confidence interval, HDL high-density lipoprotein, and LDL low-density lipoprotein.
†	The effect is the difference per each copy of the allele in units of standard deviation change (in LDL cholesterol level, HDL cholesterol level, and the natural
logarithm of triglyceride level), millimeters of mercury (for systolic and diastolic blood pressure), or the odds ratio for disease (for type 2 diabetes) for
carriers as compared with noncarriers.

blood pressure were performed on a set of
146,562 samples from the CHARGE+ consortium, and the results for tests of association
with type 2 diabetes were extracted from publicly
available databases. Additional details of the
sources and samples for these analyses of risk
factors are provided in Tables S4 and S5 in the
Supplementary Appendix.
We found a significant association between
SVEP1 p.D2702G and blood pressure (Table 3,
and Table S7 in the Supplementary Appendix).
The allele associated with an increased risk of
coronary artery disease was also associated with
higher systolic blood pressure (0.94 mm Hg
higher for each copy of the allele among allele
carriers, P = 3.0×10−7) and higher diastolic blood
pressure (0.57 mm Hg higher for each copy of
the allele among allele carriers, P = 4.4×10−7). We
did not find an association between SVEP1
p.D2702G and any plasma lipid trait. In contrast,
ANGPTL4 p.E40K was not associated with blood
pressure but instead was found to be associated
1138
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with significantly lower levels of triglycerides
(approximately 0.3 standard deviation units lower
for each copy of the allele among allele carriers,
P = 1.6×10−13) (Table 3) and with higher levels of
high-density lipoprotein (HDL) cholesterol (approximately 0.3 standard deviation units higher
for each copy of the allele among allele carriers,
P = 8.2×10−11) (Table 3). In a conditional analysis,
these effects appeared to be at least partially
independent of each other (Table S8 in the Supplementary Appendix). We did not observe any
significant association between ANGPTL4 p.E40K
and LDL cholesterol level (Table 3). Both SVEP1
p.D2702G and ANGPTL4 p.E40K were nominally
associated with type 2 diabetes in a direction
concordant with the associated risk of coronary
artery disease.

Table 3. Association between Low-Frequency Variants and Traditional Risk
Factors.*
Variant and Risk Factor

of

The finding that a missense allele in ANGPTL4
reduced the risk of coronary artery disease, potentially by reducing triglyceride levels, raised the
possibility that complete loss-of-function variants
in ANGPTL4 may have an even more dramatic effect on triglyceride concentrations and the risk
of coronary artery disease. We therefore examined sequence data for the seven protein-coding
exons of ANGPTL4 in 6924 patients with earlyonset myocardial infarction and 6834 controls
free from coronary artery disease (details of the
patients and controls are provided in Table S3 in
the Supplementary Appendix). We discovered a
total of 10 variants that were predicted to lead to
loss of gene function (Fig. 1A, and Table S9 in
the Supplementary Appendix), carried by 28
heterozygous persons; no homozygous or compound heterozygous persons were discovered.
Carriers of loss-of-function alleles had significantly lower levels of triglycerides than did noncarriers (a mean of 35% lower among carriers,
P = 0.003) (Fig. 1B, and Table S10 in the Supplementary Appendix), with no significant difference in LDL or HDL cholesterol levels. Moreover,
we found a lower risk of coronary artery disease
among carriers of loss-of-function alleles (9 carriers among 6924 patients vs. 19 carriers among
6834 controls; odds ratio for disease, 0.47;
P = 0.04) (Table S11 in the Supplementary Appendix). A similar investigation was performed
for the 48 protein-coding exons of SVEP1; however, only 3 loss-of-function allele carriers were
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Coding Variation in LPL and the Risk
of Coronary Artery Disease

On the basis of the fact that a loss of ANGPTL4
function was associated with reduced risk of
coronary artery disease and that ANGPTL4 inhibits lipoprotein lipase (LPL), one would expect
a gain of LPL function to also be associated with
a lower risk of coronary artery disease, whereas a
loss of LPL function would be expected to be
associated with a higher risk. In observations
consistent with these expectations, we found a
low-frequency missense variant in LPL on the
exome array that was associated with an increased
risk of coronary artery disease (p.D36N; minorallele frequency, 1.9%; odds ratio for disease,
1.13; P = 2.0×10−4) (Table S12 in the Supplementary Appendix); previous studies have shown that
this allele (also known as p.D9N) is associated
with LPL activity that is 20% lower in allele carriers than in noncarriers.8 We also identified a
nonsense mutation in LPL on the exome array that
was significantly associated with a reduced risk
of coronary artery disease (p.S447*; minor-allele
frequency, 9.9%; odds ratio, 0.94; P = 2.5×10−7)
(Table S12 in the Supplementary Appendix). Contrary to most instances in which the premature
introduction of a stop codon leads to loss of
gene function, this nonsense mutation, which
occurs in the penultimate codon of the gene,
paradoxically induces a gain of LPL function.9

Discussion
Through large-scale exomewide screening, we
identified a low-frequency coding variant in
ANGPTL4 that was associated with protection
against coronary artery disease and a low-frequency coding variant in SVEP1 that was associated with an increased risk of the disease. Moreover, our results highlight LPL as a significant
contributor to the risk of coronary artery disease
and support the hypothesis that a gain of LPL
function or loss of ANGPTL4 inhibition protects
against the disease.
ANGPTL4 has previously been found to be
involved in cancer pathogenesis and wound
healing.10 Previous functional studies also revealed that ANGPTL4 regulates plasma triglyceride concentration by inhibiting LPL.11 The minor
n engl j med 374;12

A ANGPTL4
c.547+1G→A
p.R161*
p.Q133*
p.C80Vfs12*
5

p.W350*
p.Q362Rfs13*
p.Y363*
p.Q369*
p.W383*
3

p.G313Afs84*

B Effects of ANGPTL4 Loss-of-Function Mutations on Lipid Levels
Mutation noncarriers

Mutation carriers
P=0.003

300

Mean Plasma Lipid Level (mg/dl)

discovered (2 carriers among 6924 patients vs.
1 carrier among 6834 controls).

200

P=0.30

100

0

P=0.19

LDL Cholesterol HDL Cholesterol

Triglycerides

Figure 1. Loss-of-Function Alleles in ANGPTL4 and Plasma Lipid Levels.
Panel A shows the loss-of-function mutations discovered by sequencing
the seven exons of ANGPTL4 in 9731 persons of European ancestry. The
locations of the individual mutations are depicted along the length of the
ANGPTL4 gene, starting at the 5′ end (left), along with the predicted functional effect. An asterisk indicates the introduction of a premature stop
codon. Panel B shows the mean plasma lipid levels according to loss-offunction allele carrier status. T bars indicate standard deviations. P values
were calculated from a linear regression (with the use of a logarithm transformation in the case of triglycerides) with covariates of age, sex, and study.
HDL denotes high-density lipoprotein, and LDL low-density lipoprotein.

allele at p.E40K has previously been associated
with lower levels of triglycerides and higher levels
of HDL cholesterol.12 We now provide independent confirmation of these lipid effects. In vitro
and in vivo experimental evidence suggests that
the lysine allele at p.E40K results in destabilization of ANGPTL4 after its secretion from the cell
in which it was synthesized. It may be that the
p.E40K variant leads to increases in the enzymatic activity of LPL because of this destabilization.13 Previous, smaller studies produced conflicting results regarding p.E40K and the risk
of coronary artery disease14,15; we now provide
robust support for an association between p.E40K
and a reduced risk of coronary artery disease.
To provide confirmatory orthogonal evidence
that a loss of ANGPTL4 function is associated
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with a decreased risk of coronary artery disease,
we searched for loss-of-function mutations in
this gene. We found that ANGPTL4 loss-of-function mutations were associated with substantially lower triglyceride levels (35% lower than in
persons who were not carriers of a loss-of-function mutation), and we also found that these
loss-of-function alleles were associated with a
53% lower risk of coronary artery disease. The
identification by Dewey et al.16 of additional
ANGPTL4 inactivating mutation carriers, now
reported in the Journal, provides further evidence
of the association between a loss of ANGPTL4
function and lower triglyceride levels and a reduced risk of coronary artery disease.
Because ANGPTL4 inhibits LPL, we examined
coding variants in LPL that were present on the
exome array. A gain-of-function mutation in LPL
was found to be associated with protection
against coronary artery disease, whereas a partial loss-of-function mutation was associated
with increased risk. These data corroborate evidence that has connected the risk of myocardial
infarction to coding-sequence mutations in two
other genes encoding proteins that modulate
LPL activity: apolipoprotein A57 and apolipoprotein C3.17,18 Thus, the available human genetic
evidence, including our current findings, is
coalescing around the conclusion that, in addition
to elevated levels of LDL cholesterol, disordered
metabolism of triglyceride-rich lipoproteins
through the LPL pathway contributes substantively to coronary artery disease (Fig. 2). These
data also support the hypothesis that therapeutic
modulation of this pathway — either by direct
enhancement of LPL activity or by blocking of
the effects of natural LPL inhibitors, such as
ANGPTL4 (Fig. 2B) — should reduce both triglyceride levels and the risk of coronary artery
disease. Studies involving inhibitors of APOC3,19
of ANGPTL4,16,20 or of other inhibitory regulators in the LPL pathway will be needed to address this possibility.
The identification of a disease-associated missense variant in SVEP1 points to a potentially
novel genetic mechanism leading to atherosclerosis. SVEP1 is a cell-adhesion molecule that acts
as a ligand for integrin α9β121; knockdown of
SVEP1 alters inflammatory signaling in a cellular
model of sepsis.22 Although we observed that the
low-frequency variant that was associated with
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an increased risk of coronary artery disease was
also associated with significantly higher blood
pressure, the latter effect was modest as compared with that found in a previous study, in
which a genetically mediated 1.6–mm Hg increase in systolic blood pressure was associated
with a 10% increased risk of coronary artery
disease23 (in our study, SVEP1 p.D2702G was associated with an approximately 1–mm Hg increase
in systolic blood pressure but a 14% increased
risk of coronary artery disease). Thus, the exact
mechanism by which SVEP1 contributes to coronary artery disease and the extent to which hypertension and diabetes mediate this risk remain to
be clarified.
Several limitations of our study deserve consideration. In our samples, approximately three
quarters of the variants on the array were either
monomorphic (i.e., only the human reference
allele was observed among the persons in the
discovery cohort) or very rare (frequency below
0.1%); therefore, we cannot make any estimates
of their contribution to the risk of coronary
artery disease. Moreover, we estimate that the
Illumina HumanExome BeadChip, version 1.0,
covers only approximately 80% of coding variants in persons of European ancestry that have
an allele frequency of 0.1% or higher (Fig. S1 in
the Supplementary Appendix). Furthermore, despite a combined sample size of more than
120,000 persons in the discovery cohort, we had
only 80% power to detect an odds ratio of approximately 1.5 for variants with a minor-allele
frequency of 0.5% (or an odds ratio of approximately 2.0 for variants with a minor-allele frequency of 0.1%) at the required stringent level of
significance (Fig. S2 in the Supplementary Appendix). Hence, analyses of even larger data sets
and more comprehensive coverage of exonic
variants may reveal further coding variants associated with the risk of coronary artery disease.
In summary, through large-scale exomewide
screening, we identified several low-frequency
coding variants that are associated with either
an increased risk of or protection against coronary artery disease. Our results highlight the
LPL pathway as a significant contributor to the
risk of coronary artery disease and support
speculation that therapeutic modulation of this
pathway might be protective against coronary
artery disease.
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Figure 2. Genetic Variants Affecting the Lipoprotein Lipase Pathway and the Risk of Coronary Artery Disease.
Panel A shows normal physiological function of lipoprotein lipase (LPL) and regulation of LPL by gene products of ANGPTL4, APOC3,
and APOA5. LPL, which is both transported across and anchored to capillary endothelial cells by the protein GPIHBP1, normally hydrolyzes the triglycerides that are present in circulating lipoproteins and reduces the plasma triglyceride level. Its activity is reduced by
ANGPTL4 and APOC3 and increased by APOA5. Not shown here are other important regulators of LPL activity, including APOC2 and
ANGPTL3. Green arrows indicate enhancers, and red blocked arrows indicate inhibitors. IDL denotes intermediate-density lipoprotein,
and VLDL very-low-density lipoprotein. Panel B shows altered function of LPL in mutation carriers. Mutations affecting LPL and proteins interacting with LPL are shown, along with expected effect on LPL activity, plasma triglyceride levels, and risk of coronary artery
disease. LPL loss of function refers to p.D36N, and gain of function refers to p.S477* (see Table S12 in the Supplementary Appendix).
ANGPTL4 loss of function refers to both p.E40K and loss-of-function mutations (Tables S9, S10, and S11 in the Supplementary Appendix).
APOC317,18 and APOA57 loss of function refers to multiple loss-of-function mutations.
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SHARING DATA IN A PUBLIC HEALTH EMERGENCY
The case for sharing data, and the consequences of not doing so, have been brought into stark relief by the Ebola and Zika
outbreaks. In response, the New England Journal of Medicine has become a journal signatory to the following statement.
“In the context of a public health emergency of international concern, it is imperative that all parties make available any information
that might have value in combatting the crisis. As research funders and journals, we are committed to working in partnership to
ensure that the global response to public health emergencies is informed by the best available research evidence and data.
Journal signatories will make all content concerning the Zika virus free access. Any data or preprint deposited
for unrestricted dissemination ahead of submission of any paper will not preempt later publication in these journals.
Funder signatories will require researchers undertaking work relevant to public health emergencies to establish mechanisms
to share quality-assured interim and final data as rapidly and widely as possible, including with public health and research
communities and the World Health Organization.
We urge other journals and research funders to make the same commitments.”
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